Regulation of RUNX3 tumor suppressor gene expressionin cutaneous melanoma

Clinical Cancer Research

Volumn 15, Issue 9, 2009, Pages 2988-2994

  Kitago, Minoru ^a   Martinez, Steve R ^a   Nakamura, Takeshi ^a   Sim, Myung Shin ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; TRANSCRIPTION FACTOR RUNX3;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DISEASE PROGRESSION; DNA METHYLATION; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MELANOMA; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 65649092616     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3172     Document Type: Article

References (41)

1. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54:131-149
2. Ito Y. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 2004;23:4198-4208
3. Araki K, Osaki M, Nagahama Y, et al. Expression of RUNX3 protein in human lung adenocarcinoma: implications for tumor progression and prognosis. Cancer Sci 2005;96:227-231
4. Cohen MM, Jr. RUNX genes, neoplasia, and cleidocranial dysplasia. Am J Med Genet 2001;104:185-188
5. Hiramatsu T, Osaki M, Ito Y, Tanji Y, Tokuyasu N, Ito H. Expression of RUNX3 protein in human esophageal mucosa and squamous cell carcinoma. Pathobiology 2005;72:316-324
6. Li J, Kleeff J, Guweidhi A, et al. RUNX3 expression in primary and metastatic pancreatic cancer. J Clin Pathol 2004;57:294-299
7. Oshimo Y, Oue N, Mitani Y, et al. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology 2004;71:137-143
8. Wei D, Gong W, Oh SC, et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res 2005;65:4809-4816
9. Javed A, Barnes GL, Pratap J, et al. Impaired intranuclear trafficking of RUNX2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci U S A 2005;102:1454-1459
10. Young DW, Hassan MQ, Pratap J, et al. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by RUNX2. Nature 2007;445:442-446
11. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113-124
12. Hussein MR, Roggero E, Tuthill RJ, Wood GS, Sudilovsky O. Identification of novel deletion loci at 1p36 and 9p22-21in melanocytic dysplastic nevi and cutaneous malignant melanomas. Arch Dermatol 2003;139:816-817
13. Poetsch M, Dittberner T, Woenckhaus C. Microsatellite analysis at 1p36.3 in malignant melanoma of the skin: fine mapping in search of a possible tumour suppressor gene region. Melanoma Res 2003;13:29-33.
14. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004;23:4014-4022
15. Takeuchi H, Fujimoto A, Tanaka M, Yamano T, Hsueh E, Hoon DS. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 2004;10:2351-2358
16. Koyanagi K, Kuo C, Nakagawa T, et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 2005;51:981-988
17. Koyanagi K, O'Day SJ, Gonzalez R, et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 2005;23:8057-8064
18. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS. Epigenetic inactivation of RAS association domain family protein1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003;63:1639-1643
19. Umetani N, de Maat MF, Mori T, Takeuchi H, Hoon DS. Synthesis of universal unmethylated control DNA by nested whole genome amplification with phi29 DNA polymerase. Biochem Biophys Res Commun 2005;329:219-223
20. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, Hoon DS. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res 2004;10:7475-7483
21. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets, and gene nomenclature. Nucleic Acids Res 2006;34:D140-4.
22. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005;33:e179.
23. Tang F, Hajkova P, Barton SC, Lao K, Surani MA. MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res 2006;34:e9.
24. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297
25. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-531
26. Mueller W, Nutt CL, Ehrich M, et al. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 2007;26:583-593
27. Nomoto S, Kinoshita T, Mori T, et al. Adverse prognosis of epigenetic inactivation in RUNX3 gene at 1p36 in human pancreatic cancer. Br J Cancer 2008; 98:1690-1695
28. Sakakura C, Miyagawa K, Fukuda KI, et al. Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis. Oncogene 2007;26:5927-5938
29. Kim TY, Lee HJ, Hwang KS, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 2004; 84:479-484
30. Inoue K, Shiga T, Ito Y. RUNX transcription factors in neuronal development. Neural Dev 2008;3:20.
31. Nakamura S, Senzaki K, Yoshikawa M, et al. Dynamic regulation of the expression of neurotrophin receptors by RUNX3. Development 2008;135:1703-1711
32. Silver D, Pavan W. The origin and development of neural crest-derived melanocytes. In: Hearing VJ, Leong SP, editors. From melanocytes to melanoma. Totowa: Humana Press; 2006. p. 3-26.
33. Fujiwara Y, Chi DD, Wang H, et al. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res 1999;59:1567-1571
34. Ambros V. The functions of animal microRNAs. Nature 2004;431:350-355
35. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 2004;5:R13.
36. Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature 2005;435:745-746
37. Bemis LT, Chen R, Amato CM, et al. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res 2008;68:1362-1368
38. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866
39. Zhang B, Pan X, Cobb GP, Anderson TA. Micro- RNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1-12.
40. Ito K, Lim AC, Salto-Tellez M, et al. RUNX3 attenuates β-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 2008;14:226-237
41. Lin YC, You L, Xu Z, et al. Wnt inhibitory factor-1gene transfer inhibits melanoma cell growth. Hum Gene Ther 2007;18:379-386